
Malu Martinez Chantar has an extensive experience in the study of liver biology, particularly NAFLD, to which she has dedicated all of her professional career. She has a very high-level track of record productivity with publications in a very high-percentage of publications of the 1st decile in the category of Nature, Nature Communications, Cell Metabolism, Hepatology and Gastroenterology. Since 2005, when she initiated her laboratory as a Principal Investigator and got “tenure” at CIC bioGUNE, Spain, her laboratory work has been continuously financially supported by government and private funding competitive sources, both national and international. Remarkably, she has been co-PI of NIH with Dr. Lu (USC, Keck School of Medicine, Los Angeles, USA) in the field of liver disease. She was one of the partners in an ambitious European project so called HEPADIP Consortium, which was created in response to the topic of the 3rd call for proposals in the EU FP6 Programme. Actually, she is the coordinator of the Traslational Area of the National Institute for the study of Liver and Gastrointestinal Diseases (CIBEREHD) and the Scientific Advisory Board of national and international centers. Finally, she is part of the select multinational group "Women in Hepatology" composed only of women, experts in the field of Hepatology, with representatives from Europe and USA.
She has also held several collaborations with Pharmaceutical companies with 5 resultant patent applications and 4 licensed products. Finally, she has maintained a closed collaboration with the company OWL Metabolomics in the development of OWLiver® Care and OWLiver®, two non-invasive assays for fatty liver screening and for NASH diagnosis.
Latest Publications
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
-
Associate Principal Investigator
Alfonso Martínez de la Cruz
-
Irene González Recio
-
Arantza Sanz Parra
-
Jorge Simon Espinosa
-
Miren Bravo Garmendia
-
Álvaro Eguileor Giné
-
Carmen Fernández Rodriguez
-
Ruben Rodriguez
-
Teresa Cardoso
-
Sofia Lachiondo
-
Maria Mercado Gómez
-
Begoña Rodríguez Iruretagoyena
-
Naroa Goikoetxea
-
Marina Serrano
-
Claudia Gil Pitarch
Members
Latest Publications
NFATc4: New hub in NASH development
Martinez-Chantar, ML;Foti, M
JOURNAL OF HEPATOLOGY
2020-12-01
Multi-Omics Integration Highlights the Role of Ubiquitination in CCl4-Induced Liver Fibrosis
Mercado-Gomez, M;Lopitz-Otsoa, F;Azkargorta, M;Serrano-Maci, M;Lachiondo-Ortega, S;Goikoetxea-Usandizaga, N;Rodriguez-Agudo, R;Fernandez-Ramos, D;Bizkarguenaga, M;Gutierrez-de Juan, V;Lectez, ...
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
2020-12-01
The L-alpha-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis
Fondevila, MF;Fernandez, U;Gonzalez-Rellan, MJ;Lima, ND;Buque, X;Gonzalez-Rodriguez, A;Alonso, C;Iruarrizaga-Lejarreta, M;Delgado, TC;Varela-Rey, M;Senra, A;Garcia-Outeiral, V;Novoa, E;Iglesias, ...
HEPATOLOGY
2020-11-13
Nutraceutical Properties of Polyphenols against Liver Diseases
Simon, J;Casado-Andres, M;Goikoetxea-Usandizaga, N;Serrano-Macia, M;Martinez-Chantar, ML
NUTRIENTS
2020-11-01
Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment
Martinez-Chantar, ML;Avila, MA;Lu, SC
CANCERS
2020-10-01
Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitisviaAMPK and mTOR regulation
Fernandez-Ramos, D;Lopitz-Otsoa, F;Delacruz-Villar, L;Bilbao, J;Pagano, M;Mosca, L;Bizkarguenaga, M;Serrano-Macia, M;Azkargorta, M;Iruarrizaga-Lejarreta, M;Sot, J;Tsvirkun, D;van Liempd, SM;Goni, ...
WORLD JOURNAL OF GASTROENTEROLOGY
2020-09-14
Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis
Shahrouzi, P;Astobiza, I;Cortazar, AR;Torrano, V;Macchia, A;Flores, JM;Niespolo, C;Mendizabal, I;Caloto, R;Ercilla, A;Camacho, L;Arreal, L;Bizkarguenaga, M;Martinez-Chantar, ML;Bustelo, XR;Berra, ...
CANCERS
2020-09-01
Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease
Gomez-Santos, B;de Urturi, DS;Nunez-Garcia, M;Gonzalez-Romero, F;Buque, X;Aurrekoetxea, I;de Juan, VG;Gonzalez-Rellan, MJ;Garcia-Monzon, C;Gonzalez-Rodriguez, A;Mosteiro, L;Errazti, G;Mifsut, ...
AGING CELL
2020-07-07
Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation
Barbier-Torres, L;Fortner, KA;Iruzubieta, P;Delgado, TC;Giddings, E;Chen, YDH;Champagne, D;Fernandez-Ramos, D;Mestre, D;Gomez-Santos, B;Varela-Rey, M;de Juan, VG;Fernandez-Tussy, P;Zubiete-Franco, ...
NATURE COMMUNICATIONS
2020-07-03
A Novel Serum Metabolomic Profile for the Differential Diagnosis of Distal Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma
Macias, RIR;Munoz-Bellvis, L;Sanchez-Martin, A;Arretxe, E;Martinez-Arranz, I;Lapitz, A;Gutierrez, ML;La Casta, A;Alonso, C;Gonzalez, LM;Avila, MA;Martinez-Chantar, ML;Castro, RE;Bujanda, L;Banales, ...
CANCERS
2020-06-01